Document is current
Any future updates will be listed below
-
Authors
Chladek, Michael https://orcid.org/0000-0001-9649-4479
Meza, Maria Virginia
Wang, Jessie
Sae-Hau, Maria https://orcid.org/0000-0002-5160-7721
Buenfil, Ana
Turnbull, James https://orcid.org/0009-0009-3467-9932
Zaman, Faraz https://orcid.org/0000-0002-0758-4630
Despiegel, Nicolas
-
Funding
Funding for this research was provided by:
Amgen
- License Information
-
More Information
Article History
Received: 30 January 2025
Accepted: 26 March 2025
First Online: 13 April 2025
Declarations
:
: Authors Ana Buenfil, Michael Chladek, and James Turnbull are employees of IQVIA, which was contracted by Amgen to conduct the study, and James Turnbull has stock ownership with IQVIA. Authors Nicolas Despiegel, Faraz Zaman, and Jessie Wang are employees of Amgen. Maria Virginia Meza is a contract worker for Amgen. Author Maria Sae-Hau is an employee of The Leukemia & Lymphoma Society, which was contracted by Amgen to participate in conducting the study.
: This interview study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice and applicable regulatory requirements. The protocol, informed consent form, and all other recruitment, interview, and patient-facing materials received approval from the WIRB Copernicus Group (WCG) institutional review board (study number 1324824). All participants provided informed consent.
: The authors would like to thank all the patients who participated in this study.
